37 CFR § 1.633(i) and (j) preliminary motions
g. Cabilly preliminary motion 7 under 37 CFR 1.633(c)(2) to add claims 61-
67 to the ‘611 application (Paper 75).
h. Cabilly contingent preliminary motion 8 under 37 CFR 1.633(f) to be
accorded priority benefit for the filing date of the '419 application for claims 61-67 (Paper 76).
I. Cabilly contingent preliminary motion 9 under 37 CFR § 1.633(f) to be
accorded priority benefit for the filing date of the '457 application for claims 61-67 (Paper 77).
Other Glaxo motions
19. Glaxo filed twelve miscellaneous motions.
20. Glaxo miscellaneous motions 1-4 and 6-9 have been decided. In particular:
Glaxo miscellaneous motion 1 was denied (Paper 39),
Glaxo miscellaneous motions 2 and 3 were denied (Paper 99),
Glaxo miscellaneous motion 4 was granted (Paper 128), and
Glaxo preliminary motions 6, 7, and 9 were granted (Paper 163).
21. Glaxo miscellaneous motion 5 is contingent upon the denial of Glaxo
miscellaneous motion 4 (Paper 121 at 2) and thus is DISMISSED as moot.
22. Glaxo miscellaneous motion 8 was returned to Glaxo (Paper 163) because it was
said to be replaced by Glaxo miscellaneous motion 9 and thus is DISMISSED as moot (Paper
142 at 2).
23. Glaxo miscellaneous motions 10, 11, and 12 are treated as motions to suppress
evidence (Paper 179).
-10-
Page: Previous 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Last modified: November 3, 2007